Taiwan Liposome Co., Ltd. – Trademark Portfolio
Entity Type: 03
Taiwan Liposome Co., Ltd. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 10 trademarks are registered and 3 are pending. Notable registered marks include TLC, LIPAD, NANOX, NANO X, and VIGJORY. The owner is based in Taipei.
11F-1, No.3, Yuan Cyu St., Nankang Dist.
Taipei , TW
Showing of trademarks Trademarks
Trademark Classifications
Taiwan Liposome Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Taiwan Liposome Co., Ltd. have?
Taiwan Liposome Co., Ltd. has 25 U.S. trademarks filed with the USPTO. Of these, 10 registered, 3 pending, 5 abandoned, 7 cancelled.
What trademark classes does Taiwan Liposome Co., Ltd. file in?
Taiwan Liposome Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Taiwan Liposome Co., Ltd.'s most well-known trademarks?
Taiwan Liposome Co., Ltd.'s registered trademark portfolio includes well-known marks such as TLC, LIPAD, NANOX, NANO X, and VIGJORY. These are among 10 currently registered trademarks in the portfolio.
What is Taiwan Liposome Co., Ltd.'s trademark registration success rate?
Taiwan Liposome Co., Ltd. has a 45% trademark registration rate, with 10 out of 22 resolved applications resulting in successful registration. Currently, 3 applications are pending review.